Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2022 - 2023)

Gyre Therapeutics has reported Preferred Stock Liabilities over the past 5 years, most recently at $64.5 million for Q4 2023.

Quarterly Preferred Stock Liabilities rose 93.72% to $64.5 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $64.5 million through Dec 2023, up 93.72% year-over-year, with the annual reading at $64.5 million for FY2023, 93.72% up from the prior year.
Preferred Stock Liabilities was $64.5 million for Q4 2023 at Gyre Therapeutics, up from $33.3 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $64.5 million in Q4 2023 and troughed at $33.3 million in Q4 2022.